The Wharton Moneyball Post Game Podcast

Share

Wharton Moneyball: Why Generalists Triumph & A Look Behind the Magic of Jeopardy

Ep. 152

Show from 5/29/19


In this episode of Wharton Moneyball we have our full cast of hosts and they talk to current Jeopardy champion James Holzhauer about strategy on the show! Plus they get into the benefits of being a generalist with author of the brand new book Range: Why Generalists Triumph in a Specialized World. Stay tuned for their weekly over unders at the end! Tune in


Guests:

David Epstein is author of the brand new book RANGE: Why Generalists Triumph in a Specialized World, and of the New York Times best seller The Sports Gene. He was previously an investigative reporter at ProPublica–covering everything from medical misdiagnosis to drug cartels–and before that a senior writer at Sports Illustrated.

Check out his website: https://www.davidepstein.com/

Follow him on Twitter: @DavidEpstein


James Holzhauer is the current Jeopardy Champion who is all over the news. He has eclipsed $2 million in earnings in just 27 games. For reference it took Ken Jennings 74 games to win all of his $2.5 million. His correct response rate on the show is at 97% and when he is not on Jeopardy he is a professional sports better who resides in Las Vegas.

Follow him on Twitter: @James_Holzhauer

Check out his progress on Jeopardy here: https://www.facebook.com/jeopardyjames/

More Episodes

7/22/2020

7/22/2020: COVID-19, Sports, David Fajgenbaum

David Fajgenbaum, MD, MBA, MSc is a groundbreaking physician-scientist, disease hunter, and bestselling author of the acclaimed memoir, Chasing My Cure: A Doctor's Race to Turn Hope Into Action. Fajgenbaum went from being a beast-like college Quarterback to receiving his last rites while in medical school and nearly dying four more times battling Castleman disease. To try to save his own life, he spearheaded an innovative approach to research and discovered a possible treatment that has put him into an extended remission. Now, he is spreading this approach to advance cures for other diseases and sharing lessons he learned about living from nearly dying through Chasing My Cure.One of the youngest individuals ever appointed to the faculty at Penn Medicine and the top 1 percent youngest grant awardees of a leading NIH grant, Dr. Fajgenbaum is co-founder and executive director of the Castleman Disease Collaborative Network (CDCN) and Associate Director, Patient Impact, for the Penn Orphan Disease Center. He has been recognized on the Forbes 30 Under 30 list, as a top healthcare leader by Becker's Hospital Review, the Global Genes RARE Champion of Hope: Science awardee, and one of three recipients--including Vice President Joe Biden--of a 2016 Atlas Award from the World Affairs Council of Philadelphia. Before co-founding the CDCN, Dr. Fajgenbaum co-founded and led the Actively Moving Forward Support Network, a non-profit organization dedicated to supporting grieving college students. Dr. Fajgenbaum has been profiled in a cover story by The New York Times as well as by Good Morning America, CNN, and the Today Show, among others.Dr. Fajgenbaum earned a BS from Georgetown University magna cum laude with honors and distinction, MSc from the University of Oxford, MD from the University of Pennsylvania Medical School, and MBA from The Wharton School. He is a former Division I college quarterback, state-champion weight lifter, and co-founder of a national grief support network.